Sorafenib-induced palmoplantar hyperkeratosis.
Publication/Presentation Date
6-1-2008
Abstract
Sorafenib is an oral multikinase inhibitor used in the treatment of renal cell carcinoma. As with single kinase inhibitors, cutaneous adverse events have been reported with sorafenib, specifically a hand-foot reaction complicated by hyperkeratosis. The authors highlight the case of a 51-year-old Caucasian woman treated for metastatic renal cell carcinoma who presented with well-defined tender erythematous callosities of the fingers and feet, following a dosage increase of sorafenib. A dose reduction decreased the symptoms, but the hyperkeratosis persisted. This adverse response may represent a novel event differing from traditional hand-foot syndrome.
Volume
7
Issue
6
First Page
588
Last Page
589
ISSN
1545-9616
Published In/Presented At
Lountzis, N. I., & Maroon, M. S. (2008). Sorafenib-induced palmoplantar hyperkeratosis. Journal of drugs in dermatology : JDD, 7(6), 588–589.
Disciplines
Medicine and Health Sciences
PubMedID
18561593
Department(s)
Department of Medicine
Document Type
Article